• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4595849)   Today's Articles (42)   Subscriber (49336)
For: Kim SW, Planchard D, Feng PH, Karaseva N, Kim T, Lee C, Poltoratskiy A, Yanagitani N, Powar S, Huang X, Howarth P, Jänne P, Kobayashi K. 366MO Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.359] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]  Open
Number Cited by Other Article(s)
1
EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC. J Thorac Oncol 2021;16:1788-1792. [PMID: 34716002 DOI: 10.1016/j.jtho.2021.06.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 06/05/2021] [Accepted: 06/07/2021] [Indexed: 11/21/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA